Literature DB >> 10052474

Hepatitis virus infection in haemodialysis patients from Moldavia.

A Covic1, L Iancu, C Apetrei, D Scripcaru, C Volovat, I Mititiuc, M Covic.   

Abstract

BACKGROUND: Although the epidemiology of hepatitis B (HBV) and C (HCV) now seems well established for Western European countries, in Central and Eastern Europe < 50% of all dialysis centres routinely test for hepatitis C antibodies since testing is not available or is not applied to all patients. This study describes the prevalence, risk factors and clinical significance of HBV and HCV infection for the haemodialysis population of the North Eastern region of Romania, Moldavia.
METHODS: The presence of HBV antigens was determined with an ELISA kit (Wellcome, Abbot) and HCV antibodies with the ELISA-3 Ortho-HCV, third generation test. The following individual data were collected: gender, age, duration of dialysis, rural/urban domicile, actual and previous HBV status, actual HCV status, known acute, clinically evident hepatitis episodes in the last 3 years, monthly alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) levels, complete biochemical hepatic assessment at the time of the study, transfusions for the past 3 years and family history.
RESULTS: HBV and HCV prevalences were 17% (stable over the last 3 years) and 75%, respectively; co-infection was seen in 10% of the subjects. Hospitalization (nosocomial infection) for HBV, blood transfusions and duration on dialysis for HCV, emerged as the main risk factors for hepatitis infection. Socio-economic conditions appear to be equally important for HCV infection, since the prevalence was significantly higher among patients from rural, underdeveloped areas than urban areas (80.8 vs 60.3%), and infection was already present in a large proportion of patients (47%) before starting dialysis, without being related to previous disease duration or blood transfusions. HBV and/or HCV was not associated with a worse clinical or biochemical profile at the time of the study. However, infected patients had significantly more previous cytolytic episodes, with higher, transient increases in ALAT and ASAT levels.
CONCLUSIONS: HCV infection is endemic among dialysis centres in Moldavia. Apart from previously well-known risk factors for hepatitis infection, our study demonstrates the negative impact of socio-economic underdevelopment. Simple measures such as enforced general asepsia rules, careful disinfection and equipment sterilization, routine testing of patients from economically disadvantaged areas and monthly, serial determination of hepatic enzymes should be the common practice in dialysis centres in Romania.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052474     DOI: 10.1093/ndt/14.1.40

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  19 in total

1.  Immunogenicity of a recombinant hepatitis B vaccine (Euvax-B) in haemodialysis patients and staff.

Authors:  S A Tele; R M Martins; C L Lopes; M A dos Santos Carneiro; K P Souza; C F Yoshida
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

Review 2.  Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis.

Authors:  Soheil Ashkani-Esfahani; Seyed Moayed Alavian; Mohammad Salehi-Marzijarani
Journal:  World J Gastroenterol       Date:  2017-01-07       Impact factor: 5.742

3.  Distribution of HCV genotypes in patients with end-stage renal disease according to type of dialysis treatment.

Authors:  Haldun Selcuk; Mehmet Kanbay; Murat Korkmaz; Gurden Gur; Ali Akcay; Hande Arslan; Nurhan Ozdemir; Ugur Yilmaz; Sedat Boyacioglu
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

4.  Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.

Authors:  H Hinrichsen; G Leimenstoll; G Stegen; H Schrader; U R Fölsch; W E Schmidt
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 5.  Hepatitis C and its impact on renal transplantation.

Authors:  Jose M Morales; Fabrizio Fabrizi
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

6.  Prevalence and associations of hepatitis C viremia in hemodialysis patients at a tertiary care hospital.

Authors:  S Jasuja; A K Gupta; R Choudhry; V Kher; D K Aggarwal; A Mishra; M Agarwal; A Sarin; M K Mishra; V Raina
Journal:  Indian J Nephrol       Date:  2009-04

7.  Hepatitis B viral infection in maintenance hemodialysis patients: a three year follow-up.

Authors:  Ya-Li Cao; Shi-Xiang Wang; Zuo-Min Zhu
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

8.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

Review 9.  Management of hepatitis C virus infection in hemodialysis patients.

Authors:  Yue-Cheng Yu; Yue Wang; Chang-Lun He; Mao-Rong Wang; Yu-Ming Wang
Journal:  World J Hepatol       Date:  2014-06-27

10.  Improving hepatitis B vaccine efficacy in end-stage renal diseases patients and role of adjuvants.

Authors:  Mohammad Hossein Somi; Babak Hajipour
Journal:  ISRN Gastroenterol       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.